Magnevist

DRUG5 trials

Conditions

Breast CancerBreast Cancer DiagnosisCentral Nervous System DiseasesMagnetic Resonance ImagingMagnetic Resonance Imaging Contrast AgentsPeripheral Vascular DiseasePositron Emission Tomography

Phase 3

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

CompletedNCT00395460

BayerCentral Nervous System Diseases

Start: 2006-09-30End: 2007-04-30Updated: 2015-06-08

Crossover Study With MultiHance vs a Comparator for Peripheral MRA

CompletedNCT00408083

Bracco Diagnostics, IncPeripheral Vascular Disease

Start: 2006-12-31End: 2008-12-31Target: 100Updated: 2009-03-27

Multihance Versus Magnevist in Breast MRI

CompletedNCT00486473

Bracco Diagnostics, IncBreast Cancer

Start: 2007-07-31End: 2009-12-31Target: 130Updated: 2010-07-15

Phase 4

Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis

NCT01956409

National Taiwan University HospitalBreast Cancer Diagnosis, Magnetic Resonance Imaging, Positron Emission Tomography

Start: 2012-09-30End: 2017-03-31Target: 80Updated: 2016-02-04

Unknown Phase

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

CompletedNCT03910114

Vanderbilt University Medical CenterMagnetic Resonance Imaging Contrast Agents

Start: 1990-07-01End: 2019-04-01Updated: 2019-04-10

Related Papers

Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial).